The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Advancements in gene editing for SCD: reni-cel and base editing platforms
Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses advancements in gene editing for sickle cell disease (SCD). Renizgamglogene autogedtemcel (reni-cel) is a gene editing medicine that is more specific compared to others, and there are ongoing trials investigating base editing as a novel gene editing platform. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS
